Therapies for the treatment of ITP
| Clinical situation . | Therapy option . |
|---|---|
| Initial treatment of newly diagnosed ITP | Corticosteroids |
| Dexamethasone | |
| Methylprednisolone | |
| Prednis(ol)one | |
| IVIg | |
| Anti-D (licensed and available for ITP in only a few countries) | |
| Subsequent treatment | Medical therapies |
| Medical therapies with robust evidence | |
| Rituximab | |
| TPO-RAs: eltrombopag, avatrombopag, romiplostim | |
| Fostamatinib | |
| Medical therapies with less robust evidence | |
| Azathioprine | |
| Cyclophosphamide | |
| Cyclosporine A | |
| Danazol | |
| Dapsone | |
| Mycophenolate mofetil | |
| TPO-RA switch | |
| Vinca alkaloids | |
| Surgical therapies | |
| Splenectomy | |
| Treatment of patients failing multiple therapies | Accessory splenectomy |
| Alemtuzumab | |
| Combination of initial and subsequent therapies | |
| Combination chemotherapy | |
| Clinical trials | |
| HSCT | |
| Splenectomy, if not already performed | |
| Supportive care |
| Clinical situation . | Therapy option . |
|---|---|
| Initial treatment of newly diagnosed ITP | Corticosteroids |
| Dexamethasone | |
| Methylprednisolone | |
| Prednis(ol)one | |
| IVIg | |
| Anti-D (licensed and available for ITP in only a few countries) | |
| Subsequent treatment | Medical therapies |
| Medical therapies with robust evidence | |
| Rituximab | |
| TPO-RAs: eltrombopag, avatrombopag, romiplostim | |
| Fostamatinib | |
| Medical therapies with less robust evidence | |
| Azathioprine | |
| Cyclophosphamide | |
| Cyclosporine A | |
| Danazol | |
| Dapsone | |
| Mycophenolate mofetil | |
| TPO-RA switch | |
| Vinca alkaloids | |
| Surgical therapies | |
| Splenectomy | |
| Treatment of patients failing multiple therapies | Accessory splenectomy |
| Alemtuzumab | |
| Combination of initial and subsequent therapies | |
| Combination chemotherapy | |
| Clinical trials | |
| HSCT | |
| Splenectomy, if not already performed | |
| Supportive care |
Treatment options for ITP are listed in alphabetical order and do not imply a preferred treatment option.
HSCT, hematopoietic stem cell transplantation; TPO-RA, TPO receptor agonist.